Entecavir

BARACLUDE, ENTECAVIR

Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor

NADAC/unit $0.2218

No Shortage Tier 1: 50.2% PA Req: 2.4% 8 Manufacturers 16 ANDAs

Entecavir suppresses hepatitis B virus replication.

vs. brand BARACLUDE: Generic saves up to 98% per unit

Covered Lives

Market Intelligence

2025-10-08 Class II Recall: Zydus Pharmaceuticals (USA) Inc

2025-09-24 Class II Recall: Zydus Pharmaceuticals (USA) Inc

Generic Manufacturers

AMNEAL PHARMACEUTICALSAUROBINDO PHARMA LTDBRIGHTGENE BIO-MEDICAL TECHNOLOGY CO LTDBRISTOL MYERS SQUIBBCIPLA LTDCONBA USA INCHETERO LABS LTD UNIT VYUNG SHIN PHARMACEUTICAL INDUSTRIAL CO LTDZYDUS PHARMACEUTICALS USA INC

Explore in the Ecosystem

rxsaver.aiCompare prices for Entecavir drfinder.aiFind doctors who prescribe Entecavir clinicalrx.aiClinical profile: Entecavir rxnews.aiLatest news about Entecavir

Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.